Literature DB >> 31771461

Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist.

Ketevan Berekashvili1, Alicia M Zha1, Mohammed Abdel-Al2, Xu Zhang3, Jazba H Soomro4, Samuel J Prater2, James C Grotta5.   

Abstract

Background and Purpose- There is uncertainty among many emergency medicine physicians about the decision to give intravenous tPA (tissue-type plasminogen activator), which limits its use. A checklist approach has been suggested as a solution. We compared agreement on tPA treatment in suspected acute ischemic stroke patients between emergency medicine residents (EMRs) using a checklist and vascular neurology fellows (VNFs). Methods- Every suspected acute stroke patient brought to our comprehensive stroke center emergency room within 4.5 hours from symptom onset was prospectively evaluated simultaneously and independently by VNFs and EMRs. The latter used a tPA screening checklist, which included guideline exclusion criteria to help with their treatment decision. Agreement was determined using kappa (k) statistics. Results- Over 6 months, 60 patients were enrolled; 10% large vessel atherosclerosis, 18% cardioembolism, 12% small vessel, 12% cryptogenic, and 47% mimic. Forty-two percent were deemed tPA eligible by the EMR, 30% by the VNF, and 37% by the vascular neurology faculty. There were no complications in any tPA-treated patients. Agreement was substantial between EMR and VNF (κ=0.68 [95% CI, 0.49-0.87]) and between EMR and vascular neurology faculty (κ=0.69 [95% CI, 0.50-0.87]). Stroke mimics were the main cause of disagreement between EMR and VNF (κ=0.24 [95% CI, -0.15 to 0.63]) and between EMR and vascular neurology faculty (κ=0.35 [95% CI, -0.08 to 0.78]). Conclusions- Our data suggest that with the aid of a checklist, EMRs can accurately treat stroke patients with tPA. Areas for improvement include recognition of stroke mimics. Further studies are warranted to evaluate checklist-enhanced tPA treatment to allay emergency medicine physician uncertainty and expand the use of tPA.

Entities:  

Keywords:  emergency medicine; faculty; humans; neurology; tissue-type plasminogen activator

Mesh:

Substances:

Year:  2019        PMID: 31771461      PMCID: PMC7046078          DOI: 10.1161/STROKEAHA.119.026948

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  Geographic access to acute stroke care in the United States.

Authors:  Opeolu Adeoye; Karen C Albright; Brendan G Carr; Catherine Wolff; Micheal T Mullen; Todd Abruzzo; Andrew Ringer; Pooja Khatri; Charles Branas; Dawn Kleindorfer
Journal:  Stroke       Date:  2014-08-26       Impact factor: 7.914

Review 2.  Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke.

Authors:  Paul Trouillas; Rüdiger von Kummer
Journal:  Stroke       Date:  2006-01-05       Impact factor: 7.914

3.  Understanding interobserver agreement: the kappa statistic.

Authors:  Anthony J Viera; Joanne M Garrett
Journal:  Fam Med       Date:  2005-05       Impact factor: 1.756

4.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

5.  Is a Neurologist Needed to Diagnose Acute Stroke in the Emergency Department?: Too Many Cooks Might Spoil the Broth.

Authors:  Jagannadha Avasarala
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

6.  Agreement Among Stroke Faculty and Fellows in Treating Ischemic Stroke Patients With Tissue-Type Plasminogen Activator and Thrombectomy.

Authors:  Ahmad-Riad Ramadan; Mary Carter Denny; Farhaan Vahidy; Jose-Miguel Yamal; Tzu-Ching Wu; Amrou Sarraj; Sean Savitz; James Grotta
Journal:  Stroke       Date:  2016-11-22       Impact factor: 7.914

Review 7.  Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  Bart M Demaerschalk; Dawn O Kleindorfer; Opeolu M Adeoye; Andrew M Demchuk; Jennifer E Fugate; James C Grotta; Alexander A Khalessi; Elad I Levy; Yuko Y Palesch; Shyam Prabhakaran; Gustavo Saposnik; Jeffrey L Saver; Eric E Smith
Journal:  Stroke       Date:  2015-12-22       Impact factor: 7.914

8.  Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis.

Authors:  Georgios Tsivgoulis; Ramin Zand; Aristeidis H Katsanos; Nitin Goyal; Ken Uchino; Jason Chang; Efthimios Dardiotis; Jukka Putaala; Anne W Alexandrov; Marc D Malkoff; Andrei V Alexandrov
Journal:  Stroke       Date:  2015-03-19       Impact factor: 7.914

9.  Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Edward C Jauch; Jeffrey L Saver; Harold P Adams; Askiel Bruno; J J Buddy Connors; Bart M Demaerschalk; Pooja Khatri; Paul W McMullan; Adnan I Qureshi; Kenneth Rosenfield; Phillip A Scott; Debbie R Summers; David Z Wang; Max Wintermark; Howard Yonas
Journal:  Stroke       Date:  2013-01-31       Impact factor: 7.914

10.  Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.

Authors:  Steven R Messé; Pooja Khatri; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Deepak L Bhatt; Maria V Grau-Sepulveda; Margueritte Cox; Eric D Peterson; Gregg C Fonarow; Lee H Schwamm
Journal:  Neurology       Date:  2016-09-14       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.